Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.37 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198031 | 0.90 | HDAC1 (0.47) | HDAC1HDAC6FLT4KDRP2RY1 | |
| SCHEMBL16038513 | 0.88 | HDAC1 (0.46) | HDAC1HDAC6FLT4KDRP2RY1 | |
| SCHEMBL16041215 | 0.88 | HDAC1 (0.46) | HDAC1HDAC6FLT4KDRP2RY1 | |
| SCHEMBL21873559 | 0.83 | HDAC1 (0.42) | HDAC1HDAC6FLT4KDRP2RY1 | |
| SCHEMBL21873561 | 0.83 | HDAC1 (0.42) | HDAC1HDAC6FLT4KDRP2RY1 | |
| SCHEMBL29259454 | 0.82 | CCNB2 (0.42) | HDAC1HDAC6FLT4KDREGFR | |
| SCHEMBL16039838 | 0.82 | HDAC1 (0.42) | HDAC1HDAC6FLT4KDRP2RY1 | |
| SCHEMBL29259736 | 0.82 | CDK5 (0.44) | HDAC1HDAC6EGFRERBB3TMIGD3 | |
| SCHEMBL38651357 | 0.79 | HDAC1 (0.39) | HDAC1HDAC6FLT4KDREGFR | |
| SCHEMBL31314694 | 0.78 | CDK5 (0.37) | HDAC1HDAC6KDREGFRERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | HDAC1 2622/4885HDAC6 337/4885FLT4 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.